PANBESY®
APPETITE SUPPERANT

PRESENTATION
- Each red and natural colour PANBESY® capsule contains 15 mg Phentermine Hydrochloride.
- Each dark blue and natural colour PANBESY® capsule contains 30 mg Phentermine Hydrochloride.

PANBESY®, Phentermine Hydrochloride, is an anorexiant.
The PANBESY® retard process induces a slow, gradual and continued release of Phentermine Hydrochloride and is therefore well tolerated.

INDICATIONS
For short term use as an adjunct to the treatment of some patients with moderate to severe obesity.

SIDE EFFECTS
Phentermine Hydrochloride is usually well tolerated in the therapeutic dosage, though individuals vary considerably in their reactions. Among the side effects which are relatively common are dryness of the mouth, restlessness, headache, insomnia, irritability, dizziness and tremor. Larger doses may give rise to fatigue, mental depression, an increase in blood pressure, fever, cardiovascular reactions, disorientation, hallucinations and convulsions. Palpitation, tachycardia, overstimulation, euphoria, dysphoria, rarely psychotic episodes at recommended doses. Unpleasant taste, diarrhoea, constipation, other gastrointestinal disturbances, urticaria, impotence, changes in libido.

OVERDOSAGE
Symptoms: Initially irritability, agitation, disorientation and tremor may occur, followed by cardiac arrhythmias, convulsions, hallucinations and coma.
Treatment: The stomach should be emptied by emesis or stomach tube and washed out with water if the preparation has been ingested within the last three or four hours. Diazepam, preferably by mouth (cautiously by intravenous injection) should be used to control marked excitement and convulsions. Provided renal function is adequate, elimination of phentermine may be assisted by acidification of the urine by agents such as lysine hydrochloride or arginine hydrochloride.

RECOMMENDED DOSAGE
Adult: 1-2 capsules of 15 mg a day before breakfast.
Adult: 1 capsule of 30 mg a day before breakfast.

CONTRAINDICATIONS
Epilepsy; hypersensitivity to sympathomimetic amines; advanced arteriosclerosis; severe hypertension; children under 12 years; hyperexcitability; patients with cardiovascular disease; hyperthyroidism; glaucoma.
Patients with a history of drug abuse. During or 14 days following administration of monoamine oxidase inhibitors.

WARNINGS
The administration of PANBESY® should be avoided in children under the age of 12 years and during pregnancy and lactation.
Tolerance to the anorectic effect usually develops within a few weeks. When this occurs, the recommended dose should not be exceeded in an attempt to increase the effect: rather the drug should be discontinued. Phentermine Hydrochloride may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle: the patient should therefore be cautioned accordingly.

Caution is to be exercised in prescribing Phentermine Hydrochloride for patients with even mild hypertension. Insulin requirements in diabetes mellitus may be altered in association with the use of Phentermine Hydrochloride and the concomitant dietary regimen. Phentermine Hydrochloride may decrease the hypotensive effect of guanethidine. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. The possibility of abuse of Phentermine Hydrochloride should be kept in mind when evaluating the desirability of including the drug as part of a weight reduction program.

SHELF LIFE
3 years from the date of manufacture.

STORAGE CONDITIONS
Store in a cool, dry place below 25°C.
KEEP OUT OF REACH OF CHILDREN.

PACKAGING
Packs containing 200 PANBESY® capsules, each dosed at 15 mg of Phentermine Hydrochloride (Retard Pellets).
Packs containing 200 PANBESY® capsules, each dosed at 30 mg of Phentermine Hydrochloride (Retard Pellets).

TRADEMARK REGISTERED BY:
Eurodrug Laboratories

MANUFACTURER:
Osmopharm S.A.
Via alle Fornaci
6930 Bedano
Switzerland

Revision January 2019

19XA12E99.A01